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Summary After 10 years of screening for breast cancer by mammography in Nijmegen, the predictive value
of positive screening results (PV+) was evaluated. The percentage of women with breast cancer in the group
of referred women (PV+) for women under age 50 was 16-26%, regardless of the number of screening
examinations they had. The percentage of women with breast cancer in the group of women who were
biopsied was 25-40%, regardless of the number of examinations. For women aged 50 and over the predictive
value was 34-57% and 58-90% respectively. It was further evaluated whether characteristics such as age,
Quetelet index, parity, and Wolfe-classification could be used to increase the PV+ in women who were
identified as positive by mammography. A logistic regression model analysis showed that true-positive and
false-positive cases differ significantly only in terms of age and breast complaints. Although the model had a
good fit, it could not be used to distinguish false-positive from true-positive test results.
Since 1975 five screening rounds have been carried out in a
non-randomised screening project with biennial mammo-
graphy in the city of Nijmegen. The results of breast cancer
screening projects such as the HIP-trial in the United States
(Shapiro et al., 1982), the DOM-project in Utrecht (Collette
et al., 1984), the Nijmegen screening project (Verbeek et al.,
1984) and the Swedish trial (Tabair et al., 1985) show a
considerable reduction of breast cancer mortality. But even
though it is no longer disputed that early detection and early
treatment are beneficial, some unsolved problems remain
with respect to how they can best be achieved. One of the
problems inherent to screening is that a number of women
who have been identified by mammography as suspect for
malignancy will turn out to be false-positive cases at an
additional clinical examination. One of these additional
procedures is mammographic localization of the lesion and
biopsy. Undergoing preoperative mammographic localization
and surgical biopsy is an emotional strain on the patient;
the procedures are expensive and, like any invasive
procedure, they are not without risks of complication.
It is important therefore to aim for a screening test that
yields as few false-positive test results as possible. When the
Nijmegen project had run for 10 years, and when new
mammographic equipment and a different viewing technique
had been used for some years, it was decided to evaluate the
positive predictive value (PV+), which is the percentage of
women with breast cancer in the total group of referred
women.
Attempts were made to reduce the number of false-
positive screening mammograms before proceeding to
excision biopsy. To do so, it was ascertained whether the
PV+ of the screening test could be increased by using
certain epidemiologic characteristics of the referred women
in addition to the mammographic data without increasing
the number of false-negative test results.
Subjects and methods
All data came from the Nijmegen (150,000 inhabitants)
programme. This population-based project started in
January 1975. Single-view mammography was carried out as
the only screening examination every 2 years. It was
standard procedure to make a single lateral view of both
breasts, which, in 1982, was changed into a medio-lateral-
oblique view. At the same time the mammographic
apparatus was replaced: the senographe fx with 0.6mm focus
was replaced by a senographe 500t with 0.3 mm focus.
In the first screening round women born in the period
1910-1939 (n=23,000) were invited. In the subsequent
screening rounds women born before 1910 (n=7,700) were
invited too; in the fifth screening round the cohort of women
born in the period 1940-1944 (n = 3,900) was invited.
All mammograms are read by the radiologist, who decides
if referral is necessary. If so, the general practitioner is
informed and the patient requested to contact him for
admission to hospital. Physical examination by a surgeon
and complete mammography (including magnified cone
down views and detail-views if necessary) are thereafter
undertaken. There is mutual consultation between the
radiologist, pathologist and surgeon concerned who decide if
any further investigation is called for, e.g. a mammographic
check after 6 months, ultrasound examination, fine-needle
aspiration cytology, or surgical biopsy. If biopsy results
prove positive, the actual treatment is started.
In 5 screening rounds 801 women were referred to hospital
to be clinically examined after a single view at the screening
centre: breast cancer was histologically confirmed in 302 of
them within 1 year of referral. Ten women were not
classified because no physical and histological examination
was done: six of them were 78 or older; three of them
refused clinical examination; and one was not classified
because of delay in diagnostic procedure of more than one
year. One of the women who initially refused examination
had a biopsy 4 years after referral, which revealed cancer. Of
the remaining 9 women, 2 have moved away and 3 died (as
at January 1986). The remaining 4 are still alive without
breast cancer, according to the Nijmegen breast cancer
registry. The 489 women left were classified false-positive,
which means no breast cancer was diagnosed within one
year of referral.
Women with a false-positive test result were compared
with those with a true-positive result in terms of a number of
characteristics. Those included in this survey are listed in
Table III. They were obtained through blank forms which
the women were asked to fill in prior to the screening
examination. The characteristic 'breast complaints' included
pain not related to menses, tumours in breast or axilla,
changes in skin or nipple secretion.
The mammograms of the breast contralateral to those that
precipitated referral, were classified according to the Wolfe
classification into Ni, P1, P2, DY breast parenchymal
patterns (Wolfe, 1976). The classification was applied to the
contralateral breast to avoid information bias. The aim was
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to detect any characteristics that showed significant
differences in the two groups of true-positive and false-
positive cases and to see if they could be used to distinguish
true-positive from false-positive cases at a stage where
mammography identified all of them as positive.
Relative risks were calculated by the Odds Ratio
approximation for each of the characteristics and a logistic
regression model was used for adjustment; the regression
coefficients were estimated by maximum likelihood (Breslow
& Day, 1980).
Results
Table I shows the predictive value positive (PV+), which is
defined as the probability of having breast cancer given an
initially positive mammogram.
In the screening period the PV+ increased from 29.8% in
the first screening round in 1975/76, to 53.8% in the fifth
round in 1983/84.
It is possible that these crude positive predictive values are
influenced by two factors, viz. the number of previous
screening examinations at the time of referral and age. If
mammograms from previous screening examinations are
available, the radiologist is more likely to notice suspect
mammographical changes when he has to decide whether or
not to refer the patient. Age is another important factor
since it is generally known that many women under age 50
have a dense parenchymal breast pattern, and on a
mammogram, this pattern is more likely to mask a
developing cancer than a fatty parenchymal breast pattern.
Because Table I contains a mixture of first (prevalence)
screens and consecutive (incidence) screens, the PV + in
Table II was calculated for regular attenders only. It shows
the number of women screened, referrals, biopsies and true-
positives. The PV+ are given according to referral and
biopsy, for each number of examinations and stratified for
two age-groups.
Women under age 50 at the time of referral have a PV+
of 16-26%, regardless of the number of examinations. There
was no significant trend (X2-test for linear trend in
proportions: X2 =0.26, df= 1 P=0.62) towards a higher
PV+ for higher numbers of screening examinations. The
linear trend for PVY+ for biopsies was not significant either:
x2=-.l3' P=0.73.
For women aged 50 or over at referral, the PV+ at the
first screening examination was 43.9%; for those referred at
the fifth examination the PV+ was 57.1%. Again there was
no significant trend towards a higher PV+ for higher
numbers of examinations (X2=0.22, df=l P=0.65). Now
the linear trend for biopsies turned out to be statistically
significant (X2 = 13.78, P<0.005).
Table III presents a comparison of all true-positive and
false-positive cases in relation to 15 characteristics. The
association between a certain characteristic and a true-
positive test result is expressed in terms of relative risk
estimates. For example (see Table III): 21.2% of the women
under 50 at referral turn out to be true-positive while 46.7%
of the women aged 50 or older at referral are true-positive.
A woman aged 50 or older at referral will have a relative
risk of 3.25 of having breast cancer compared with a woman
who is less than 50 at referral.
The characteristics of age, Quetelet index, menopause,
Wolfe-classification, and breast complaints yield relative
risks that differ significantly from unity.
Because some of the characteristics are interdependent, the
data were analysed in a logistic regression model, including
all above mentioned variables, in order to extract the
Table I Distribution of referred women according to screening result and screening round
Round I Round 2 Round 3 Round 4 Round 5
Test result 1975/76 1977/78 1979/80 1981/82 1983/84 Total
True-positive 75 75 48 47 57 302
False-positive 177 116 73 74 49 489
Referred-total 252 191 121 121 106 791
Predictive value (%) 29.8 39.3 39.7 38.8 53.8 38.2
Table II Screening results according to number
examination
of examinations and age at
(a) Women under age 50
Ist exam 2nd exam 3rd exam 4th exam 5th exam Total
Screened 12,893 6,944 4,894 3,439 2,241 -
Referred 129 56 31 27 10 253
Biopsy 84 36 22 21 5 168
True-positive 27 9 8 7 2 53
PV+ (ref.) 20.9 16.1 25.8 25.9 20.0 20.9
PV+ (biop.) 32.1 25.0 36.4 33.3 40.0 31.5
Specificity 99.9 99.9 99.8 99.7 99.9 -
(b) Women aged 50 or over
1st exam 2nd exam 3rd exam 4th exam 5th exam Total
Screened 13,695 10,907 9,204 8,140 6,892 -
Referred 228 92 73 53 49 495
Biopsy 172 62 42 24 31 331
True-positive 100 41 30 18 28 217
PV+ (ref.) 43.9 44.6 41.1 34.0 57.1 43.8
PV+(biop.) 58.1 66.1 71.4 75.0 90.3 65.6
Specificity 99.8 99.8 99.8 99.8 99.8 -
'Number of examinations' does not necessarily correspond to 'round number' in
Table I, e.g., a woman may have had her first examination in 1983/84, round 5.SCREENING FOR BREAST CANCER BY MAMMOGRAPHY 669
relevance of each separate characteristic. Only the variables
of age and breast complaints yielded significant regression
coefficients: the regression coefficient for the continuous
variable of age (year) was 0.0606 and for breast complaints
0.8398 (1 = yes, 0 =no). A non-significant result was
estimated by a x2 goodness of fit P=0.54, which implies a
model that is not in contradiction with the data. To check
whether this well-fitting model could be used to distinguish
true-positive from false-positive mammographic results, the
logistic model was applied to the data on age and breast
complaints for each individual: the chance for each woman
to be true positive was estimated by the model. Next, these
chance rates were stratified into 8 chance groups (0.1-0.2,
0.20.3,... 0.8-0.9) and within each chance group the
observed number of true-positive cases was compared with
the observed number of false-positive cases. Figure 1 shows
these numbers.
No marked line can be drawn to distinguish false-positive
from true-positive results, without a substantial loss of true-
positive test results as a result of distributional overlap. If
for example, a line is drawn at 0.2 percent, this means that
women with a chance of more than 0.2 (predicted by the
model on the basis of their age and complaints) would be
referred for biopsy, whereas women with a chance lower
than 0.2 would not. According to Figure 1, 68 unnecessary
biopsies (68/489=14%) would be prevented at the cost of 10
cancers (10/301 =3%). This model, therefore, cannot be used
in addition to mammographic results to distinguish false-
positive from true-positive cases.
Discussion
The PV+ for women under the age 50 is half the PV+ for
women aged 50 or over. Since the PV+ is a function of the
sensitivity and the specificity of the test and the prevalence
of breast cancer in the screened population, we have to look
for an explanation of this difference in these parameters. The
specificity rates in both age groups are very high and almost
the same, viz. over 99%, but both the sensitivity of the test
and the prevalence of breast cancer are lower for women
under age 50 compared with women of 50 or older
Table III Relative Risks of being classified true-positive after referral, for 15 characteristics
Relative risk P-value
(estimated as (estimated by
Characteristic Risk group
Age at referral
Quetelet index
kgm-2
Marital status
Parity
Age at first child
birth
Breast feeding
Age at menarche
Regular menses
Menopause
Age at menopauseb
Familial breast
cancer
Oral contraceptive
use
Breast complaints
Breast aberrations
in historyd
Wolfe classification
>50
46.7%
>25
43.0%
Never married
38.5%
0 child
31.3%
.25
37.9%
Never
33.3%
.15
32.5%
No
30.9%
Yes
46.0%
50
47.9%
Yes
43.4%
Ever
30.2%
Yes
53.6%
Yes
36.1%
NI +P1
44.1%
Reference group
<50
21.2%
<25
31.3%
(Ever) married
38.1%
1 child
35.8%
<25
30.7%
Ever
36.2%
<15
36.0%
Yes
35.4%
No
26.0%
<50
41.2%
No
37.2%
Never
36.8%
No
36.6%
No
38.5%
P2 +DY
32.4%
Odds ratio) association)
3.25 P=0.0001
1.65 P=0.0009
(missing 13)
1.02 P=0.9320
0.82 P=0.2809
(missing 117)'
1.38 P=0.1145
(missing 119)'
(NRb 179)
0.89 P=0.6344
(missing 117)'
(NRb 179)
0.86 P=0.3946
(missing 147)'
0.82 P=0.5067
(missing 148)'
2.42 P=0.0001
(missing 30)
1.31 P=0.1775
(missing 170)'
(NRC 250)
1.30 P=0.1947
(missing 3)
0.74 P=0.1400
(missing 139)
2.00 P=0.0055
(missing 4)
0.98 P=0.6114
(missing 4)
1.65 P=0.0007
(missing 1)
aThe great number of missing data are due to the introduction in the second screening round
of new blank forms, which excluded these questions; bNot relevant for women without children;
CNot relevant for premenopausal women; dAberrations: operation, mastitis, cyste or radiation in
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Figure 1 Distribution of the 787 true-positive and false-positive
test result cases according to chance rates, predicted by the
model:
Pr = 1/(1 +exp(-(4.005 +0.060x1 +0.8398x2)))
Pr =chance of having a true-positive test result
Xi=age at referral
x2 =breast complaints (0 = no, 1 =yes)
(Hendriks, 1982; Verbeek, 1985). The sensitivity rates of the
test, based on the occurrence rate of interval cancer in a
2-year observation period, are 45-60% for women under 50
but 60-80% for the older age group. Some of the interval
cancers of the breast, however, may well have been non-
existent at the time of this previous examination and may
have grown rapidly. There are some indications that in
women under the age of 50 a more aggressive kind of breast
cancer occurs with a faster growth rate (Meyer et al., 1984).
If this is true a relatively great proportion of the interval
cancers in this young age group will be newly developed
cancers, and consequently the above-mentioned sensitivity
rate of 45-60% would be too low. If the sensitivity and
specificity rates are equal in both age groups, then the lower
PV+ for women under 50 could only be the result of a
lower prevalence of breast cancer in this age group.
In Table I an increase in PV+ is noticeable in round 5. It
could be argued that this increase was influenced by the use
of a new mammography apparatus in 1981. The PV+ for
women under age 50 at referral did not change significantly:
before 1982 the PV+ was 19.4% (43/222) on average, and
after the replacement 31.0% (13/42); P=0.09. For women
aged 50 or over the PV+ was 43.7% (180/412) on average
before 1982, and after it was 57.4% (66/115); P<0.01.
However, a logistic regression analysis with 'yes/no
referred via new apparatus' in the multivariate model, age
included, did not yield a statistically significant result.
The PV+ in Nijmegen is high compared with other PV+
rates in the literature. In the HIP-study (Shapiro et al., 1966)
111 women age 40-64 were referred to a surgeon at their
first examination with mammography only. Twelve were
diagnosed as having breast cancer (PV+ = 11%). Later
reports on the HIP study show about a 20% biopsy positive
rate for mammography. In the BCDDP projects a PV+ rate
of 10-15% was estimated for women aged 35-74, who were
referred for surgery (Baker, 1982). The Guildford Screening
Project in England (Thomas et al., 1983) invited women aged
45-64. In the first screening round the PV+ for surgical
examination was 27.4% and the PV+ for biopsies was
36.1%. In a screening service in London (Chamberlain et al.,
1984) the PV+ for biopsies was low and decreased in the
consecutive screening rounds from 14 to 5%, which could be
the consequence of lower breast cancer prevalence (screening
was conducted after I a year, 1 year and 2 years). In 1974 a
screening project for women older than 40 was started in
Sandviken, a city in Sweden (Andersson et al., 1979). In the
third screening round in 1980 the PV+ for clinical
examination for women under age 50 was 37.5%. For
women aged 50 or older the PV+ was 60.0%. Biopsy was
performed in 27 women, 21 of whom proved to have breast
cancer: the PV+ for biopsies was 78%. In 1976 a breast
cancer screening project was started for women aged 50-69
in Malm6, Sweden (Lundgren & Helleberg, 1982). After a
complete mammographic examination 211 women were
referred for clinical examination: 45% proved to have breast
cancer. In Kopparberg, another county in Sweden, a
screening project started in 1977 (Tabtar & Gad, 1981). Up
to 1980, 1649 women, aged 39 or over, were referred for
detailed mammographic examination and 362 underwent a
biopsy. Cancer was diagnosed in 235 of them. The PV+ for
referral was 14.3%, and the PV+ for biopsies was 65%. The
DOM-project in Utrecht (de Waard et al., 1984) estimated a
PV+ of 40-57% for biopsies for women aged 50-64 in all
screening rounds.
The various PV+ rates described in the literature are
difficult to compare. The prevalence of breast cancer varies
geographically and with age. Moreover, in some instances
different screening intervals are used. Also different screening
tests are used, e.g., some including physical examination as
well. Viewing technique and mammographic equipment as
well as experience and knowledge may vary with each
project. In the US a more aggressive referral procedure
maintains a high sensitivity, most likely at the expense of
specificity and PV+. The result is that only 1 out of 10 or
even 1 out of 20 women who undergo biopsy will prove to
have breast cancer (Hall, 1986; Moskowitz & Gartside,
1982).
Another problem in comparing PV+ is the difference in
referral procedures (Rombach, 1983). The percentage of
women with breast cancer among referred women can be
estimated at various stages in the general procedure: after
single mediolateral oblique view, complete mammography,
clinical examination, or surgical biopsy. The results
presented in Table II, for instance, show different findings
depending on whether the PV+ estimation is based on the
numbers of women who were referred after single
mediolateral oblique view or on that of women who had
biopsy.
The increase in the biopsy PV+ in round five is large. As
a consequence of the high PV+ the first results from the
Nijmegen cancer registry show no high interval cancer rate
after round five.
Women with true-positive and false-positive test results
differ significantly in age and breast complaints. No
difference was found in the prevalence of familial breast
cancer, which could be due to the fact that the radiologist
may already have considered this characteristic when he
decided whether or not to refer the woman in case of
hesitation. Women who have breast complaints at the time
of an examination have, when referred, twice as high a
chance of turning out true-positive cases as women without
complaints do. One could argue that the screening
examination came too late for these women since screening is
supposed to detect breast cancer in an asymptomatic stage, of
the disease. Relatively few women, however, only 8% of the
screened population, answered the question on breast
complaints in the affirmative.
Although the groups of true-positive and false-positive
cases differ significantly in age and breast complaints, these
characteristics cannot be used to distinguish the two groups
from each other as is shown in Figure 1, i.e., the specificity,
which is very high as it is in Nijmegen, cannot be increased
any further using the investigated characteristics in addition
to mammographic results.
One could promote a more gradual referral procedure,
where women contact a surgeon only in the last resort after
a complete mammographic examination. In the first and
second screening rounds in Nijmegen 23% of all womenSCREENING FOR BREAST CANCER BY MAMMOGRAPHY 671
referred for clinical examination only received complete
mammography showing no evidence of breast cancer after
their referral; in the fifth screening round 16% did. This
means that 16-23% of all referred women would not have
contacted a surgeon in the gradual referral procedure where
complete mammography would be performed after a suspect
single oblique view. This procedure would be less of a strain
on the patient and less expensive as well. One could then aim
for a higher sensitivity of mammography for women under
age 50, at the expense of specificity. Perhaps the lower
specificity of the mammographic test in the gradual referral
procedure could be improved by the use of some specific
characteristics, in addition to mammographic results, in
order to increase the overall specificity.
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